RAFAEL HOLDINGS, INC. Other Selling, General and Administrative Expense
RAFAEL HOLDINGS, INC. (RFL) reported Other Selling, General and Administrative Expense of $403.00 thousand for the 9-month period ending 2023-04-30, per its 10-Q filed 2023-06-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherSellingGeneralAndAdministrativeExpense · last filed 2023-06-13
- RAFAEL HOLDINGS, INC. other selling, general and administrative expense for the quarter ending 2023-04-30 was $0.00, a 100.00% decline year-over-year.
- RAFAEL HOLDINGS, INC. other selling, general and administrative expense for the quarter ending 2023-01-31 was $157.00K, a 79.97% decline year-over-year.
- RAFAEL HOLDINGS, INC. other selling, general and administrative expense for the quarter ending 2022-10-31 was $246.00K, a 60.19% decline year-over-year.
- RAFAEL HOLDINGS, INC. other selling, general and administrative expense for the quarter ending 2022-07-31 was $677.00K.
- RAFAEL HOLDINGS, INC. other selling, general and administrative expense for fiscal 2022 was $2.68M, a 20.90% decline from fiscal 2021.
- RAFAEL HOLDINGS, INC. other selling, general and administrative expense for fiscal 2021 was $3.39M.
| Period end | Other Selling, General and Administrative Expense 3 month | Other Selling, General and Administrative Expense 6 month | Other Selling, General and Administrative Expense 9 month | Other Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2023-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | $157.00K derived: sum of 2 quarters · filed 2023-06-13 | $403.00K 10-Q · filed 2023-06-13 | $1.08M derived: sum of 4 quarters · filed 2023-06-13 |
| 2023-01-31 | $157.00K 10-Q · filed 2023-03-14 | $403.00K 10-Q · filed 2023-03-14 | $1.08M derived: sum of 3 quarters · filed 2023-03-14 | $1.68M derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-10-31 | $246.00K 10-Q · filed 2022-12-13 | $923.00K derived: sum of 2 quarters · filed 2022-12-13 | $1.53M derived: sum of 3 quarters · filed 2023-06-13 | $2.31M derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-07-31 | $677.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | $1.28M derived: sum of 2 quarters · filed 2023-06-13 | $2.06M derived: sum of 3 quarters · filed 2023-06-13 | $2.68M 10-K · filed 2022-10-31 |
| 2022-04-30 | $604.00K 10-Q · filed 2023-06-13 | $1.39M derived: sum of 2 quarters · filed 2023-06-13 | $2.01M 10-Q · filed 2023-06-13 | |
| 2022-01-31 | $784.00K 10-Q · filed 2023-03-14 | $1.40M 10-Q · filed 2023-03-14 | ||
| 2021-10-31 | $618.00K 10-Q · filed 2022-12-13 | |||
| 2021-07-31 | $3.39M 10-K · filed 2022-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |